← BioNTech overview

BioNTech vs Gilead Sciences: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BioNTech SE (BNTX)

Q3 2026
▼2▲1

BioNTech's cancer pipeline advances but COVID collapse and trial setback weigh

  • Cancer pipeline progress BioNTech's cancer pipeline gained traction: gotistobart showed strong Phase 3 lung cancer survival data, pumitamig advanced in kidney cancer, and Moderna/Merck's mRNA cancer vaccine success lifted sector sentiment.

    This is a key positive driver for the stock, showing pipeline potential.

  • COVID revenue collapse and guidance cut COVID revenue continues collapsing, forcing restructuring and a 2026 guidance cut to €1.6–1.9 billion, which pressures the company's financial outlook.

    This is a major negative factor affecting revenue and investor confidence.

  • Colorectal cancer trial halted BioNTech's own mRNA colorectal cancer trial was halted for futility and a survival imbalance, cutting shares and raising concerns about its pipeline.

    This is a significant setback that directly impacted the stock price.

  • Legal risks and leadership change Patent lawsuits from Arbutus/Roivant and Monsanto add legal risk, while a new CEO brings execution uncertainty and BMO downgraded the stock.

    These factors create uncertainty and negative sentiment, offsetting some positives.

September 2026
▲2▼2

Lung cancer win lifts BioNTech, but patent suit and downgrade weigh

  • Gotistobart nearly doubles lung cancer survival BioNTech and OncoC4 reported that gotistobart nearly doubled median overall survival versus chemotherapy in a Phase 3 lung cancer trial. This is the first strong sign that BioNTech's cancer pipeline can work, which supports the shares because investors have doubted the company's move beyond COVID vaccines.

    This is the period's biggest new positive and directly addresses doubts about BioNTech's cancer strategy.

  • Monsanto mRNA patent lawsuit moves forward A Delaware judge rejected BioNTech's bid to dismiss Monsanto's patent lawsuit over mRNA technology used in COVID-19 vaccines. The case can now proceed, creating legal uncertainty and potential future costs or royalties, which weighs on the shares.

    This is a new legal risk that could affect BioNTech's finances and is not in earlier reports.

  • BMO downgrade and price target cut BMO downgraded BioNTech to market perform and cut its price target to $105 from $128, citing the failed colorectal cancer trial and lower revenue guidance. Analyst downgrades can push the shares down because they signal weaker confidence in future earnings.

    This is a new analyst action that directly affects investor sentiment and the stock's perceived value.

  • Health Canada approves XFG-adapted COMIRNATY Health Canada approved BioNTech and Pfizer's XFG-adapted COVID-19 vaccine for people aged 6 months and older. This secures regulated seasonal revenue from Canada, helping offset weaker overall COVID demand and supporting the balance sheet.

    This is a new regulatory approval that adds a revenue stream and is not in earlier reports.

Latest
▲2▼2

Lung cancer win lifts BioNTech, but patent suit and downgrade weigh

  • Gotistobart nearly doubles lung cancer survival BioNTech and OncoC4 reported that gotistobart nearly doubled median overall survival versus chemotherapy in a Phase 3 lung cancer trial. This is the first strong sign that BioNTech's cancer pipeline can work, which supports the shares because investors have doubted the company's move beyond COVID vaccines.

    This is the period's biggest new positive and directly addresses doubts about BioNTech's cancer strategy.

  • Monsanto mRNA patent lawsuit moves forward A Delaware judge rejected BioNTech's bid to dismiss Monsanto's patent lawsuit over mRNA technology used in COVID-19 vaccines. The case can now proceed, creating legal uncertainty and potential future costs or royalties, which weighs on the shares.

    This is a new legal risk that could affect BioNTech's finances and is not in earlier reports.

  • BMO downgrade and price target cut BMO downgraded BioNTech to market perform and cut its price target to $105 from $128, citing the failed colorectal cancer trial and lower revenue guidance. Analyst downgrades can push the shares down because they signal weaker confidence in future earnings.

    This is a new analyst action that directly affects investor sentiment and the stock's perceived value.

  • Health Canada approves XFG-adapted COMIRNATY Health Canada approved BioNTech and Pfizer's XFG-adapted COVID-19 vaccine for people aged 6 months and older. This secures regulated seasonal revenue from Canada, helping offset weaker overall COVID demand and supporting the balance sheet.

    This is a new regulatory approval that adds a revenue stream and is not in earlier reports.

August 2026
▼2▲1

Cancer vaccine hopes clash with trial failure and weak guidance

  • Sector optimism from Moderna/Merck mRNA cancer vaccine success Moderna and Merck's Phase 3 mRNA cancer vaccine success lifted BioNTech shares about 22%, as investors bet the whole mRNA cancer field could win. BioNTech also reported promising first-in-class lung cancer data and won EU and FDA approvals for an updated COVID vaccine.

    This sector-wide rally and positive pipeline news were a major force pushing BioNTech shares up during the month.

  • Own mRNA colorectal cancer trial halted for futility and survival imbalance BioNTech's own Phase 2 mRNA colorectal cancer vaccine trial was stopped for futility and later for a survival imbalance, cutting shares 10% and then 7.5%. This directly undercut the optimism from the sector news and reminded investors that not all mRNA cancer bets will work.

    This was a major negative event that dragged BioNTech's stock down and highlighted pipeline risk.

  • 2026 revenue guidance cut on weak COVID demand BioNTech reduced its 2026 revenue guidance to €1.6–1.9 billion because COVID vaccine demand remains weak. This confirmed the company's main revenue source is still shrinking, adding pressure on the stock and raising doubts about near-term earnings.

    The guidance cut is a key negative driver that directly affects investor expectations for BioNTech's financial performance.

  • New CEO and strong cash cushion, but execution uncertainty BioNTech named a new CEO, creating strategic uncertainty, though it still holds €16.6 billion in cash. Upcoming ESMO data and a head-and-neck cancer interim analysis are key catalysts, but pipeline risk, rising competition, and execution challenges remain.

    This captures the mixed balance of a strong cash position and upcoming catalysts against leadership change and execution risks.

▼2▲1

BioNTech cuts guidance, replaces CEO, and halts a cancer vaccine trial

  • 2026 revenue guidance cut on weak COVID demand BioNTech lowered its 2026 revenue forecast to €1.6–1.9 billion from €2.0–2.3 billion, mainly because COVID-19 vaccine demand is weaker than expected. Less money coming in makes the shares less attractive, even though the company still holds €16.6 billion in cash.

    A direct cut to expected sales is a core reason the stock is under pressure.

  • New CEO named as company shifts focus Guido Oelkers will become CEO by February 1, replacing the current leadership. A new boss can bring fresh direction, but it also creates uncertainty about strategy and execution while BioNTech tries to move beyond COVID vaccines into cancer treatments.

    Leadership change is a major event that affects investor confidence and future strategy.

  • Colorectal cancer vaccine trial stopped for survival imbalance BioNTech ended a mid-stage trial of its personalized mRNA cancer vaccine in colorectal cancer after a monitoring committee saw a survival imbalance between groups. This raises doubts about the mRNA cancer strategy and sent shares down 7.5%, reminding investors that most cancer vaccine attempts still fail.

    The trial halt is a direct setback to the pipeline that investors hoped would drive future growth.

  • EU and FDA approvals for updated COVID vaccine European and U.S. regulators authorized BioNTech and Pfizer's XFG-adapted COVID-19 vaccine for the fall season. This allows sales in 27 EU countries plus the U.S., providing some near-term revenue even as overall COVID demand softens.

    Regulatory approvals secure near-term sales and partially offset the weak demand outlook.

▲2▼1

mRNA cancer hopes lift BioNTech, then its own trial fails

  • Rival's mRNA cancer win lifts whole sector Moderna and Merck's Phase 3 mRNA cancer vaccine success in melanoma sent biotech stocks to post-pandemic highs and lifted BioNTech about 22%. Investors read it as proof that mRNA cancer treatments can work, which supports BioNTech's own pipeline value.

    This sector-wide read-across was the main force pushing BioNTech shares up during the period.

  • New lung cancer data shows pipeline progress BioNTech presented first-in-class lung cancer data combining pumitamig with a B7H3 antibody-drug conjugate at a major conference. It signals real progress beyond COVID vaccines, but the company is still unprofitable and depends on late-stage trials succeeding.

    It is a company-specific pipeline update that supports the growth story behind the stock.

  • Own mRNA cancer vaccine trial fails BioNTech stopped a Phase 2 mRNA cancer vaccine trial for colorectal cancer due to futility, and shares fell 10%. The failure contrasts with Moderna's success and reminds investors that most cancer vaccine attempts still fail, so pipeline risk remains high.

    This is the period's biggest company-specific negative event and directly answers why the stock moved.

  • Competition and cash define the outlook Moderna's win increases competition in personalized cancer vaccines, but BioNTech still holds €16.6 billion in cash and securities. Upcoming data at ESMO in October and a head and neck cancer interim analysis are the next catalysts that could restore or further dent confidence.

    It gives the balanced counterweight: competitive pressure versus financial strength and upcoming catalysts.

July 2026
▲2▼2

BioNTech's cancer push grows, but COVID decline and patent suits weigh

  • Cancer pipeline advances BioNTech's mRNA cancer vaccines and personalized immunotherapies are gaining recognition, and its jointly developed drug pumitamig is being tested in a new kidney cancer trial. These moves support future revenue potential beyond COVID, which could lift the stock as investors bet on long-term growth.

    Shows new progress in BioNTech's key growth area, oncology, which is central to its future value.

  • Takeover interest and strong cash BioNTech is seen as a potential acquisition target due to its €16.8 billion in cash and a pipeline with over 25 mid- to late-stage trials. A buyout could offer a premium to the current share price, though any deal is speculative and not guaranteed.

    Highlights a possible catalyst that could significantly boost the stock if a takeover materializes.

  • COVID revenue collapse forces restructuring BioNTech is exiting German manufacturing sites and selling its peptide unit as COVID vaccine demand plunges, with revenue falling from $21.6 billion in 2021 to $3.4 billion in 2025. This reflects the loss of its main revenue source and adds uncertainty, pressuring the stock.

    Directly explains a major negative force: the sharp decline in BioNTech's core COVID business and its cost-cutting response.

  • New patent lawsuits over COVID vaccine Arbutus and Roivant have filed international patent suits against Pfizer and BioNTech over lipid nanoparticle technology used in Comirnaty, seeking injunctions and damages. This adds legal risk and potential financial liability, which could weigh on the stock.

    Represents a fresh legal threat that could result in significant costs or restrictions on a key product.

▲2▼2

BioNTech's cancer push grows, but COVID decline and patent suits weigh

  • Cancer pipeline advances BioNTech's mRNA cancer vaccines and personalized immunotherapies are gaining recognition, and its jointly developed drug pumitamig is being tested in a new kidney cancer trial. These moves support future revenue potential beyond COVID, which could lift the stock as investors bet on long-term growth.

    Shows new progress in BioNTech's key growth area, oncology, which is central to its future value.

  • Takeover interest and strong cash BioNTech is seen as a potential acquisition target due to its €16.8 billion in cash and a pipeline with over 25 mid- to late-stage trials. A buyout could offer a premium to the current share price, though any deal is speculative and not guaranteed.

    Highlights a possible catalyst that could significantly boost the stock if a takeover materializes.

  • COVID revenue collapse forces restructuring BioNTech is exiting German manufacturing sites and selling its peptide unit as COVID vaccine demand plunges, with revenue falling from $21.6 billion in 2021 to $3.4 billion in 2025. This reflects the loss of its main revenue source and adds uncertainty, pressuring the stock.

    Directly explains a major negative force: the sharp decline in BioNTech's core COVID business and its cost-cutting response.

  • New patent lawsuits over COVID vaccine Arbutus and Roivant have filed international patent suits against Pfizer and BioNTech over lipid nanoparticle technology used in Comirnaty, seeking injunctions and damages. This adds legal risk and potential financial liability, which could weigh on the stock.

    Represents a fresh legal threat that could result in significant costs or restrictions on a key product.

Gilead Sciences Inc (GILD)

Q3 2026
▲3▼1

Gilead Q3: HIV strength, new launches, but big writedown weighs

  • Q2 revenue up 10%, HIV sales up 12%, guidance raised Gilead's second-quarter revenue rose 10% to $7.8 billion, with HIV sales up 12%, and the company raised its full-year guidance. This shows the core business is growing and management is more confident about the future.

    This is the main positive force behind the stock this quarter, showing stronger sales and a brighter outlook.

  • Four planned launches and new approvals broaden business beyond HIV Gilead is preparing four new product launches and won approvals for Bixlenvo and a Trodelvy/Keytruda combination. This diversification reduces reliance on HIV and opens new revenue streams, which supports the stock.

    It shows concrete progress in expanding beyond HIV, a key part of the bull case this quarter.

  • Legal win protects Biktarvy; PAHO deal expands lenacapavir access Gilead won a legal case protecting its key HIV drug Biktarvy from generic competition, and signed a deal with PAHO to expand access to lenacapavir. These reduce competitive threats and open new markets, helping the stock.

    These events remove a major risk and add a growth avenue, both new this quarter.

  • $11.2B acquired IPR&D charge causes $8.45 GAAP loss Gilead reported a GAAP loss of $8.45 per share due to an $11.2 billion charge for acquired in-process research and development. This accounting charge weighed on reported earnings, though it doesn't reflect cash flow or ongoing operations.

    It is the main negative factor this quarter, explaining why reported earnings looked bad despite strong sales.

September 2026
▲4

Gilead's HIV franchise strengthens with legal win, access deal, and analyst backing

  • Fourth Circuit blocks illegal imports of Biktarvy A federal appeals court upheld an injunction stopping foreign versions of Gilead's top HIV drug Biktarvy from being sold in the U.S. This protects Gilead's U.S. sales and pricing power, supporting the stock.

    This legal win directly protects Gilead's largest revenue stream and removes a competitive threat.

  • PAHO deal expands lenacapavir access in Latin America Gilead and the Pan American Health Organization agreed to make HIV prevention drug lenacapavir available in 14 Latin American countries. This widens the market for Gilead's prevention portfolio, though pricing terms are still unclear.

    This expands Gilead's global reach for a key growth drug, but the financial impact depends on final pricing.

  • Morgan Stanley reaffirms Overweight on HIV prevention growth Morgan Stanley kept its buy rating on Gilead, highlighting the HIV prevention franchise. Yeztugo, a twice-yearly shot, is expected to hit $1 billion in first-year sales, with the prevention portfolio at about $4 billion annually and PrEP users more than doubling since 2022.

    Analyst backing and concrete sales targets reinforce confidence in Gilead's growth trajectory.

  • Gilead's pipeline advances with gamgertamig and anito-cel Lakefront Biotherapeutics plans registrational trials in 2027 for gamgertamig, which Gilead will commercialize. Also, Gilead's anito-cel for multiple myeloma has an FDA decision due in December. These add future growth options beyond HIV.

    Pipeline progress diversifies Gilead's revenue and offers new catalysts, though they are not yet near-term revenue.

Latest
▲4

Gilead's HIV franchise strengthens with legal win, access deal, and analyst backing

  • Fourth Circuit blocks illegal imports of Biktarvy A federal appeals court upheld an injunction stopping foreign versions of Gilead's top HIV drug Biktarvy from being sold in the U.S. This protects Gilead's U.S. sales and pricing power, supporting the stock.

    This legal win directly protects Gilead's largest revenue stream and removes a competitive threat.

  • PAHO deal expands lenacapavir access in Latin America Gilead and the Pan American Health Organization agreed to make HIV prevention drug lenacapavir available in 14 Latin American countries. This widens the market for Gilead's prevention portfolio, though pricing terms are still unclear.

    This expands Gilead's global reach for a key growth drug, but the financial impact depends on final pricing.

  • Morgan Stanley reaffirms Overweight on HIV prevention growth Morgan Stanley kept its buy rating on Gilead, highlighting the HIV prevention franchise. Yeztugo, a twice-yearly shot, is expected to hit $1 billion in first-year sales, with the prevention portfolio at about $4 billion annually and PrEP users more than doubling since 2022.

    Analyst backing and concrete sales targets reinforce confidence in Gilead's growth trajectory.

  • Gilead's pipeline advances with gamgertamig and anito-cel Lakefront Biotherapeutics plans registrational trials in 2027 for gamgertamig, which Gilead will commercialize. Also, Gilead's anito-cel for multiple myeloma has an FDA decision due in December. These add future growth options beyond HIV.

    Pipeline progress diversifies Gilead's revenue and offers new catalysts, though they are not yet near-term revenue.

August 2026
▲3▼1

Gilead Q2 beat, HIV strength, new drug approvals, but accounting loss

  • Q2 earnings beat and raised guidance Gilead's second-quarter revenue rose 10% to $7.8 billion, with HIV sales up 12% and PrEP topping $1 billion. The company raised its full-year HIV growth outlook to 9–10%, signaling confidence.

    This is the main positive force behind the stock, showing strong operational performance.

  • New HIV and cancer drug approvals The FDA approved Bixlenvo, a new single-tablet HIV regimen, and the EU expanded Trodelvy plus Keytruda for first-line triple-negative breast cancer. These expand Gilead's product lineup and market reach.

    These approvals are new revenue drivers and reinforce Gilead's competitive position.

  • Large accounting loss from acquisitions Gilead reported a GAAP loss of $8.45 per share due to $11.2 billion in acquired IPR&D charges from Arcellx, Tubulis, and Ouro Medicines. This is an accounting charge, not an operational loss, but it weighed on reported earnings.

    This explains the headline loss and why it may not reflect underlying business health.

  • Analyst confidence and pipeline progress BofA reiterated a Buy rating with a $162 target, and Gilead advanced its pipeline in oncology and a once-weekly oral HIV regimen. However, these pipeline gains are early and not yet near-term revenue.

    Analyst support and pipeline advances support the stock, though with limited immediate impact.

▲4

Gilead's HIV engine accelerates with new drug approvals and raised guidance

  • HIV sales growth guidance raised to 9–10% Gilead lifted its full-year HIV sales growth outlook to 9–10% from 8%, citing a $4 billion annualized PrEP business and strong Biktarvy. Higher expected sales mean more profit, which supports a higher stock price.

    This is a direct, new upgrade to the company's core revenue outlook, a key driver of the stock.

  • FDA approves Bixlenvo, a new single-tablet HIV regimen The FDA approved Bixlenvo, a once-daily single tablet for complex HIV cases. It is the smallest such option and the first for patients who cannot take existing single-tablet therapies, opening a new market and reinforcing Gilead's HIV leadership.

    A new product approval expands the addressable market and future revenue, directly lifting growth prospects.

  • European Commission expands Trodelvy approval in first-line TNBC The EC approved Trodelvy plus Keytruda for first-line metastatic triple-negative breast cancer, making it the only antibody-drug conjugate plus immunotherapy combo in that setting across the EU. This widens oncology sales and diversifies revenue beyond HIV.

    A major regulatory win in a new indication that boosts the oncology franchise and long-term growth.

  • Pipeline expands with MacroGenics option and once-weekly HIV data Gilead exercised an option on a MacroGenics bispecific cancer program, and positive Phase 3 results for a once-weekly oral HIV regimen with Merck were announced. These add future growth options, though they are early and not yet near-term revenue.

    New pipeline additions signal longer-term growth potential, which can support a higher valuation.

▲3▼1

Gilead's Q2 beat and raised guidance show HIV strength, but acquisition charges hit reported EPS

  • Q2 revenue beat and raised full-year guidance Gilead reported Q2 revenue of $7.8 billion, up 10% and above estimates, and raised 2026 product sales guidance to $29.8–$30.1 billion. HIV sales rose 12% to $5.7 billion, with Biktarvy up 7%. This shows the core business is growing faster than expected, which supports a higher stock price.

    This is the period's central event and directly explains the positive fundamental momentum behind GILD.

  • PrEP franchise tops $1 billion; Yeztugo persistence strong Quarterly PrEP sales doubled year-over-year to over $1 billion for the first time, led by the twice-yearly shot Yeztugo ($232 million, up 40% from Q1). Over 70% of patients stayed on Yeztugo after a year, the best among PrEP options. This growing prevention business adds a new revenue stream and reduces reliance on HIV treatment alone.

    It highlights a key new growth driver that is boosting investor confidence and future sales.

  • Large acquisition charges push reported EPS deeply negative Gilead's Q2 GAAP EPS was a loss of $8.45, and non-GAAP EPS was a loss of $6.75, due to $11.2 billion in acquired IPR&D expenses from buying Arcellx, Tubulis, and Ouro Medicines. Excluding these one-time charges, EPS would be $8.50–$8.85. The headline loss may scare some investors, but it is an accounting effect, not a cash drain on operations.

    It is the main counterweight in the period and explains why reported earnings look bad despite strong operations.

  • Analyst reiterates Buy; pipeline advances in oncology and HIV BofA reiterated a Buy rating and $162 price target, citing Yeztugo's persistence and raised guidance. Separately, European regulators backed Trodelvy plus Keytruda for first-line triple-negative breast cancer, and a once-weekly oral HIV regimen with Merck met its Phase 3 goals. These expand future sales opportunities.

    It shows external validation and pipeline progress that support the stock's longer-term growth story.

July 2026
▲4

Gilead's pipeline expands with new launches and positive HIV data

  • Four drug launches planned to diversify beyond HIV Gilead is preparing four drug launches this year, including bulevirtide for hepatitis delta and anito-cel for multiple myeloma. This diversification reduces reliance on HIV and opens new revenue streams, supporting the stock.

    This is a new strategic update that shows Gilead's growth beyond its core HIV business.

  • Positive Phase 3 results for once-weekly oral HIV regimen Gilead and Merck reported that a once-weekly oral HIV treatment maintained viral suppression in Phase 3 trials, with higher patient satisfaction. This could become the first once-weekly oral option, strengthening Gilead's HIV portfolio.

    This is a new clinical milestone that could lead to a new product and boost future sales.

  • CHMP recommends Trodelvy plus Keytruda for first-line TNBC The European regulator recommended Trodelvy combined with Keytruda for first-line metastatic triple-negative breast cancer. This expands Trodelvy's use and reinforces its role, potentially increasing sales in Europe.

    This is a new regulatory step that could lead to approval and broader use of a key drug.

  • Remdesivir evaluated in Ebola trial The WHO began an experimental Ebola trial in Congo, testing Gilead's remdesivir. If effective, it could expand remdesivir's use and demand, though the impact is uncertain and likely small.

    This is a new potential use for an existing drug, but the financial impact is not yet clear.

▲4

Gilead's pipeline expands with new launches and positive HIV data

  • Four drug launches planned to diversify beyond HIV Gilead is preparing four drug launches this year, including bulevirtide for hepatitis delta and anito-cel for multiple myeloma. This diversification reduces reliance on HIV and opens new revenue streams, supporting the stock.

    This is a new strategic update that shows Gilead's growth beyond its core HIV business.

  • Positive Phase 3 results for once-weekly oral HIV regimen Gilead and Merck reported that a once-weekly oral HIV treatment maintained viral suppression in Phase 3 trials, with higher patient satisfaction. This could become the first once-weekly oral option, strengthening Gilead's HIV portfolio.

    This is a new clinical milestone that could lead to a new product and boost future sales.

  • CHMP recommends Trodelvy plus Keytruda for first-line TNBC The European regulator recommended Trodelvy combined with Keytruda for first-line metastatic triple-negative breast cancer. This expands Trodelvy's use and reinforces its role, potentially increasing sales in Europe.

    This is a new regulatory step that could lead to approval and broader use of a key drug.

  • Remdesivir evaluated in Ebola trial The WHO began an experimental Ebola trial in Congo, testing Gilead's remdesivir. If effective, it could expand remdesivir's use and demand, though the impact is uncertain and likely small.

    This is a new potential use for an existing drug, but the financial impact is not yet clear.

Q2 2026
▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

  • FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

    This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

  • FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

    This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

  • Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

    New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

  • Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

    This is a new negative financial disclosure that could cap upside from the positive pipeline news.

June 2026
▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

  • FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

    This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

  • FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

    This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

  • Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

    New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

  • Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

    This is a new negative financial disclosure that could cap upside from the positive pipeline news.

▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

  • FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

    This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

  • FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

    This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

  • Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

    New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

  • Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

    This is a new negative financial disclosure that could cap upside from the positive pipeline news.

© 2026 MarketIVWhy